Loss of p53 Has Site-Specific Effects on Histone H3 Modification, Including Serine 10 Phosphorylation Important for Maintenance of Ploidy

Cancer Research

Volumn 63, Issue 20, 2003, Pages 6674-6679

  Allison, Simon J ^a   Milner, Jo ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE H3; LYSINE; NICOTINAMIDE; NOCODAZOLE; PROTEIN P53; SERINE; SERINE 10; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ANEUPLOIDY; ARTICLE; CANCER; CELL CYCLE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME CONDENSATION; CHROMOSOME SEGREGATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOSIS; PLOIDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; ULTRAVIOLET RADIATION;

ACETYLATION; BINDING SITES; CELL DIVISION; ENZYME INHIBITORS; G2 PHASE; HCT116 CELLS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MITOSIS; NIACINAMIDE; PHOSPHORYLATION; PLOIDIES; SERINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0142157699     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Vogelstein, B., Lane, D. P., and Levine, A. J. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000.
2. Rubbi, C. P., and Milner, J. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J., 22: 975-986, 2003.
3. Ramanathan, B., and Smerdon, M. J. Changes in nuclear protein acetylation in UV-damaged cells. Carcinogenesis (Lond.), 7: 1087-1094, 1986.
4. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig., 104: 263-269, 1999.
5. Iizuka, M., and Smith, M. M. Functional consequences of histone modifications. Curr. Opin. Genet. Dev., 13: 154-160, 2003.
6. Hooser, A. V., Goodrich, D. W., Allis, C. D., Brinkley, B. R., and Mancini, M. A. Histone H3 phosphorylation is required for the initiation, but not the maintenance, of mammalian chromosome condensation. J. Cell Sci., 111: 3497-3506, 1998.
7. Wei, Y., Yu, L., Bowen, J., Gorovsky, M. A., and Allis, C. D. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell, 97: 99-109, 1999.
8. Hsu, J-Y., Sun, Z. W., Li, X., Reuben, M., Tatchell, K., Bishop, D. K., Grusheow, J. M., Brame, C. J., Caldwell, J. A., Hunt, D. F., Lin, R., Smith, M. M., and Allis, C. D. Mitotic phosphorylation of histone H3 is governed by Ip1/aurora kinase and GIc7/PPI phosphatase in budding yeast and nematodes. Cell, 102: 279-291, 2000.
9. 2 and spreads in an ordered fashion coincident with chromosome condensation. Chromosoma (Berl.), 106: 348-360, 1997.
10. Giet, R., and Glover, D. M. Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organise the central spindle during cytokinesis. J. Cell Biol., 152: 669-682, 2001.
11. Stock, R. P., and Bialy, H. The sigmoidal curve of cancer. Nat. Biotechnol., 21: 13-14, 2003.
12. Ota, T., Suto, S., Katayama, H., Han, Z. B., Suzuki, F., Maeda, M., Tanino, M., Terada, Y., and Tatsuka, M. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/aurora B overexpression contributes to chromosome number instability. Cancer Res., 62: 5168-5177, 2002.
13. Milner, J., and Watson, J. V. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene, 5: 1683-1690, 1990.
14. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B. Role of Bax in the apoptotic response to anti-cancer agents. Science (Wash. DC), 290: 989-992, 2000.
15. Jenuwein, T., and Allis, C. D. Translating the histone code. Science (Wash. DC), 293: 1074-1079, 2001.
16. Agalioti, T., Chen, G., and Thanos, D. Deciphering the transcriptional histone acetylation code for a human gene. Cell, 111: 381-392, 2002.
17. Gray, S. G., and Eckstrom, T. J. The human histone deacetylase family. Exp. Cell Res., 262: 75-83, 2001.
18. Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., and Sternglanz, R. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. USA, 97: 5807-5811, 2000.
19. Guarente, L. Sir2 links chromatin silencing, metabolism and aging. Genes Dev., 14: 1021-1026, 2000.
20. Shore, D. The Sir2 protein family: a novel deacetylase for gene silencing and more. Proc. Natl. Acad. Sci. USA, 97: 14030-14032, 2000.
21. Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and Gu, W. Negative control of p53 by Sir2α promotes cell survival under stress. Cell, 107: 137-148, 2001.
22. Avalos, J. L., Celic, I., Muhammad, S., Cosgrove, M. S., Bocke, J. D., and Wolberger, C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell, 10: 523-535, 2002.
23. Juan, L. J., Shia, W. J., Chen, M. H., Yang, W. M., Seto, E. Lin, Y. S., and Wu, C. W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem., 275: 20436-20443, 2000.
24. Murphy, M., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine, A. J., and George, D. L. Transcriptional repression by wild-type p53 utilises histone deacetylases, mediated by interaction with mSin3a. Genes Dev., 13: 2490-2501, 1999.
25. SIRT1 functions as an NAD-dependent p53 deacetylase. Cell, 107: 149-159, 2001.
26. Langley, E., Pearson, M., Faretta, M., Bauer, U. M., Frye, R. A., Minucci, S., Pelicci, P. G., and Kouzarides, T. Human SIR2 deacetylates p53 and antagonises PML/p53-induced cellular senescence. EMBO J., 21: 2383-2396, 2002.
27. Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., and Berger, S. L. Acetylation of p53 activates transcription through recruitment of co-activators/histone acetyltransferases. Mol. Cell, 8: 1243-1254, 2001.
28. Marks, P. A., Richon, V. M., Breslow, R., and Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol., 13: 477-483, 2001.
29. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. J. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265: 17174-17179, 1990.